The problem with the conference call IMO was that not enough questions were asked. I was able to listen to the call but unable to ask questions so when the host said no more questions I was disappointed at the missed opportunity. That is why I decided to pick up the phone. Next conference call I will make myself available to ask many more questions.
My questions to Tony and Brian were focused on Medgate. How is it going so far, what is the feedback from them, how does the customer pay, what is the customer experience and process etc. I also asked about the progress of our UK team, the appointment of Mike Connell and his strategy for commercialisation. I don't think that Tony will mind me saying that he's very impressed with Mike so far and he's made a significant impact even though he's only been on board for two weeks.
I get the feeling ( and this is definitely IMO) that there are things going on behind the scenes. I'm a huge fan of the technology and if we can crack Medgate which in my opinion is more likely than not, then we're on our way. I'm completely aware that this is a speculative stock but I'm having a crack.
As for your comment @SPP1992 I certainly didn't seek investment advice from TK or BL and if I had they wouldn't have given it to me. I did however ask as many questions as I could about the business so I could make my own investment decision.
@RNClarke yes would be great to see you on the way back up. I'm completely committed for better or worse so I'm riding it all the way.
@w_i_z_z_a I understand your frustration and agree that management have made mistakes but I'll back them until EOFY. Lets see where we sit in June after Mike Connell has had a fair run at commercialising this thing and how many of the near term milestones management have ticked off. Sacking them now would be a big mistake IMO and cause us to lose momentum and credibility in the market. There are massive challenges getting this to market and the pandemic has been both a blessing and a curse. They are having a crack and trying different avenues to market and some will work and some will not. The outcome from the RB deal could be considered a failure for example but they would have learnt a hell of a lot about the DTC world and I'm personally happy if we develop a DTC ourselves then find a partner to distribute it. This seems to be managements preference and I understand that they are working on this product as we speak. We have the ability and resources to do it and we'll have much more power at the negotiating table this way.
Finally, let's just assume for fun that the Medgate deal gets done and is up and running by say June. 6000 consults per day. Even if initially only a few hundred a day use it, DX is such a unique and novel product that anyone exposed to it will be telling everyone they know about it. If we can get a foothold it will get legs! It's a great product and a great story, we just need to get it out there.
One little job management!
RAP Price at posting:
6.9¢ Sentiment: Buy Disclosure: Held
